Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use

Award Number: R01DA060692
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2029

Group Awards By:

View Award Description

Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use - Project Summary The combined opioid and stimulant use epidemic is an escalating public health emergency with numerous biological and psychological drivers and consequences, which are amplified in people with HIV (PWH) and other marginalized groups. We and others have described significant immune alterations in PWH and individuals that inject opioids and/or stimulants including increased systemic inflammation and lymphocyte dysregulation, including among B cells. This heighted inflammatory state and distorted B cell function likely contribute to increased risk and severity of infections and inflammatory co-morbidities including cardiovascular, kidney, liver, and autoimmune diseases. Although anti-retroviral therapy (ART) suppresses HIV, its ability to restore immune homeostasis is incomplete, resulting in accelerated immunological aging and associated co-morbidities; subsequently development of adjunctive interventions to mitigate these complications is ongoing. Active substance use, intoxication, and related behaviors associated with injection drug use can impact HIV viral dynamics and immune competency. Among people who inject drugs (PWID) that do not have HIV, there is a high risk for acquiring HIV, clear indications of reduced effectiveness of HIV vaccines, and altered viral dynamics in the acute stage of HIV infection; these unique factors highlight the challenges of HIV vaccine development for PWID. There is an unmet need for interventions that can restore immune homeostasis in PWID in order to improve responses to pathogens and minimize inflammatory-related co-morbidities. Metformin (MTF), the most widely prescribed drug for type 2 diabetes (T2D), may be such an intervention. Animal and human studies have demonstrated MTFs ability to reduce inflammation and enhance vaccine responses. Our central hypothesis is that MTF can mitigate the inflammation and immune dysregulation that is prevalent in PWID including among PWH, restoring immune homeostasis and responsiveness. This will be addressed through a placebo controlled, randomized clinical trial of MTF in PWH and non-PWH with a history of recent injection drug use including opioids and stimulants. Assessment of Hepatitis A/B and pneumococcal vaccine responses during this trial will allow examination of adaptive responses to pathogens of concern within these populations and serve as a surrogate for assessing their potential response to a future HIV vaccine. Vaccine outcomes will provide a metric to complement the integrated behavioral and high-resolution functional analysis of systemic and mucosal inflammation and immunity, providing mechanistic insights relevant to HIV prevention and pathogenesis. Our hypothesis will be addressed through the following aims: 1) determine the ability of MTF to mitigate inflammation and improve vaccine response in PWID, 2) determine the ability of MTF to normalize B cell phenotype and function in PWID, and 3) determine the influence of MTF on mucosal inflammation and immunity.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,107,091 )
2026	2026	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	3	5/12/2026	NON-COMPETING CONTINUATION	$1,107,091
														Subtotal = $1,107,091

Issue Date FY: 2025 ( Subtotal = $1,107,091 )
2025	2025	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Drug Use and Addiction Research Programs	002	2	4/16/2025	NON-COMPETING CONTINUATION	$1,107,091
2025	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	1	10/9/2024	NEW	$0
2025	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Drug Use and Addiction Research Programs	001	1	11/15/2024	NEW	$0
														Subtotal = $1,107,091

Issue Date FY: 2024 ( Subtotal = $1,086,368 )
2024	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Drug Use and Addiction Research Programs	000	1	9/20/2024	NEW	$1,086,368
														Subtotal = $1,086,368

Grand Total All Awards = $3,300,550

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assessment of metformin for restoration of immune homeostasis in HIV+ and HIV- individuals with a history of injection drug use

Award Number: R01DA060692

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer